𝗥𝗡𝗔 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗘𝘅𝗽𝗲𝗿𝘁 & 𝗗𝗲𝗮𝗹𝗺𝗮𝗸𝗲𝗿 with a proven track record of securing over $110M in upfront payments through 30+ partnerships, totalling over $7B in value. Leveraging 20+ years of experience in 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆, 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁,𝗮𝗻𝗱 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. I specialise in commercialising cutting-edge RNA therapeutics to improve patient access and affordability, particularly in 𝗻𝗲𝘂𝗿𝗼𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗮𝗻𝗱 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. With a Ph.D. in molecular biology and an MBA from Imperial College, I possess a deep understanding of both scientific principles and business strategy.

My key competencies include partnering, asset disposition, due diligence, technology scouting, alliance management, business intelligence, valuations, and revenue forecasting. I have a proven ability to identify and evaluate emerging technologies, build strong relationships with key stakeholders, and drive innovation in the RNA therapeutics space. By combining my scientific expertise with my business acumen, I have consistently delivered exceptional results for stakeholders and contributed to the growth of the RNA therapeutics industry.